The Tirzepatide Telehealth Market
Who is selling, at what price, on what terms, and how much of it we could verify.
Who is selling, at what price, on what terms, and how much of it we could verify.
Across the 17 programmes we price, all-in cost runs from $133 a month at the starter dose, with the cheapest first year at about $2,580 (NexLife, $215 a month at a 10 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
All-in monthly cost at 10 mg
| Programme | All-in at 10 mg | First year | Per mg | Structure | Evidence |
|---|---|---|---|---|---|
| NexLife | $215 | $2,580 | $5.38 | flat at every dose | ✓ verified at source |
| Join Fridays | $249 | $2,988 | $6.22 | flat at every dose | third-party figure |
| Yucca Health | $258 | $3,096 | $6.45 | flat at every dose | ✓ verified at source |
| Mochi Health | $278 | $3,336 | $6.95 | flat at every dose | ✓ verified at source |
| IVIM Health | $278 | $3,219 | $6.95 | rises with dose | ✓ verified at source |
| ShedRx | $289 | $3,318 | $7.22 | rises with dose | ✓ verified at source |
| SkinnyRx | $299 | $3,588 | $7.47 | flat at every dose | ✓ verified at source |
| Amble Health | $300 | $3,600 | $7.50 | flat at every dose | third-party figure |
| TrimRx | $349 | $4,188 | $8.72 | flat at every dose | ✓ verified at source |
| Lavender Sky Health | $352 | $3,971 | $8.80 | rises with dose | ✓ verified at source |
| Found | $398 | $4,776 | $9.95 | flat at every dose | third-party figure |
| MEDVi | $399 | $4,788 | $9.97 | flat at every dose | ✓ verified at source |
| Remedy Meds | $399 | $4,788 | $9.97 | flat at every dose | third-party figure |
| Eden | $408 | $4,796 | $10.20 | rises with dose | ✓ verified at source |
| Henry Meds | $509 | $6,008 | $12.72 | rises with dose | third-party figure |
| LifeMD | $548 | $6,576 | $13.70 | flat at every dose | third-party figure |
First-year all-in cost
Who left during 2026
Five of the largest names on this site no longer sell compounded tirzepatide. Ro and the WeightWatchers clinic carry brand-name products with membership billed separately. Hims closed its compounded programme to new patients after a March 2026 settlement. Calibrate operates a brand-only membership model. Noom's published figures describe brand Zepbound.
That matters for anyone reading an older comparison. A list ranking those companies for compounded tirzepatide is describing a product they do not sell, and the verification date is the only way to tell. It also means the cheap end of this market is now served by smaller operators with far less brand recognition, which raises the value of verifying the pharmacy rather than trusting the name.
The shape of the market
We track 32 tirzepatide telehealth programmes. 17 publish a price we could capture. All-in cost at a 10 mg maintenance dose runs from $215 to $548 for the identical molecule from the same category of licensed pharmacy.
That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing and margin.
Two pricing models, one of them dominant
11 of the 17 priced programmes hold one price at every strength; the rest reprice as the dose climbs. The second group's advertised figure describes roughly four weeks of a twelve-month course.
Fee structures fragment the comparison
6 programmes charge a mandatory recurring fee on top of medication. Comparisons quoting medication alone understate those programmes by the full membership, permanently.
Disclosure is the exception
Fewer than a fifth of priced programmes identify the dispensing pharmacy before purchase. That single disclosure is the one that lets a patient check a state board register, and it costs a programme nothing to publish.
What we could not establish
Shipping reliability, response times, clinical quality, or how any programme behaves when something goes wrong. None of it is measurable from outside, so none of it is in our tables.
Why this distinction changes what you pay
Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the cheapest tracked first year at $2,580 and the most expensive.
None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.
How to act on it this week
Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.
Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 17 programmes we price, that runs from $215 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
6 of those programmes charge a recurring platform fee on top of medication and 11 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
11 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
Method
Computed over one file covering 32 programmes on a single price basis: all-in monthly cost, medication plus any recurring fee, at a named dose tier. No estimates, no imputed values, and no programme excluded for reasons other than the criterion stated.
Where a finding depends on a figure we could not verify at source, it is flagged rather than rounded away.
Findings
All-in cost at a 10 mg maintenance dose spans $215 to $548 — a 2.5-times spread for the identical molecule from the same category of licensed pharmacy. 11 of 17 programmes hold one price at every dose; the rest reprice as you climb. 6 charge a mandatory recurring fee on top of medication.
Fewer than a fifth identify the dispensing pharmacy before purchase, which is the single disclosure that would let a patient verify anything independently.
Limitations
Everything here comes from published material we could access. We did not enrol, did not mystery-shop, and did not contact programmes for comment before publication. Service quality, shipping reliability and clinical depth are absent because they are not measurable from outside.
A programme that discloses something we could not find should tell us, and the record will be corrected with the date.
Reuse
Cite freely with attribution and the capture date. Journalists and analysts should take the underlying file rather than transcribing from a table, because the file carries the evidence status that a table necessarily compresses.
The failure mode this section is guarding against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew. A prepaid rate when you will pay monthly.
Each of those errors is small individually and they compound in the same direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated.
Priced correctly, the cheapest verified route sits at $215 a month all-in at a maintenance dose. Anything materially below that band deserves the question of which distortion is producing it.
Why we publish the working rather than a verdict
A single recommendation is more useful to read and less useful to act on, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and the rankings state their sort key. If you disagree with our weighting, take the file and weight it differently — that is what publishing it is for.
What would make this page wrong
A price change we have not captured, a programme leaving the market, or a figure we recorded from a third party that does not survive checking. All three have happened during 2026 and all three are logged when they do.
Prices here were captured 2026-08-05. Treat anything older than a month as needing a re-check against the provider's own page, which every programme record links directly.
How much the tirzepatide telehealth market should weigh
Less than the pharmacy question and more than the entry price. That ordering is unusual in published guidance, which typically inverts it, and it follows from what actually goes wrong: interrupted supply and unverifiable sourcing cost more than a modest price difference ever saves.
A useful test is whether a fact would change your decision if it were twice as bad. Double the price gap between the cheapest and second-cheapest verified routes and most people still choose on disclosure. Double the uncertainty about who compounded the vial and nobody should.
What a well-run programme publishes
The figure at 10 mg rather than at initiation. The pharmacy, by name. The prescriber or medical director. The cancellation notice period. And an unambiguous statement that a compounded preparation is not FDA-approved and is not reviewed for safety, effectiveness or quality before marketing.
Across the 17 priced programmes, the ones doing all of that span roughly the same price range as the ones doing none. Transparency here is a choice rather than a cost, which makes its absence informative rather than neutral.
The next step that actually moves things
Price your own course rather than reading someone else's ranking. Take the dose you expect to maintain, add every recurring fee, multiply by twelve, then ask whether you could sustain it for three years — the horizon the withdrawal evidence implies rather than the twelve months every comparison uses.
If the answer is no even at $215 a month, the useful move is checking coverage under a different indication rather than hunting a lower cash price. The cash market has a floor, and figures materially below it usually indicate one of four specific distortions.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.